Table 1. Key characteristics of assays evaluated in study of commercially available high-throughput SARS-CoV-2 assays for serosurveillance*.
| Manufacturer | Assay† | Ig target | Antigen | Assay format | Reported units | Testing laboratory |
|---|---|---|---|---|---|---|
| Ortho |
VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Ig | Total Ig | S1 | Double-antigen sandwich CLIA | S/CO | Vitalant Research Institute |
| VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG |
IgG |
S1 |
Double-antigen sandwich CLIA |
S/CO |
CTS |
|
| EUROIMMUN |
Anti-SARS-CoV-2 NCP ELISA | IgG | N | Indirect IgG EIA | S/CO | Advent Health |
| Anti-SARS-CoV-2 ELISA | IgG | S1 | Antigen sandwich ELISA | S/CO | ||
| Anti-SARS-CoV-2 QuantiVac ELISA | IgG | S1 | Antigen sandwich ELISA | RU/mL | ||
| Anti-SARS-CoV-2 ELISA |
IgA |
S1 |
Antigen sandwich ELISA |
S/CO |
||
| Roche |
Elecsys Anti-SARS-CoV-2 N on cobas | Total Ig | N | Double-antigen sandwich CLIA | COI | University of California–Davis |
| Elecsys Anti-SARS-CoV-2 S on cobas |
Total Ig |
S1/S2/RBD |
Double-antigen sandwich CLIA |
U/mL |
||
| DiaSorin |
LIAISON 28 SARS-CoV-2 TrimericS IgG |
IgG |
TrimericS |
IgG magnetic particle CLIA |
AU/mL |
British Columbia Centers for Disease Control and Prevention |
| Siemens |
ADVIA Centaur SARS-CoV-2 Total Ig | Total Ig | S1/RBD | Ag sandwich CLIA | S/CO | |
| ADVIA Centaur SARS-CoV-2 IgG |
IgG |
S1/RBD |
Ag sandwich CLIA |
Index |
||
| Abbott |
SARS-CoV-2 IgG N on ARCHITECT | IgG | N | CMIA | AU/mL | Duke Human Vaccine institute |
| SARS-CoV-2 IgG S1 on ARCHITECT | IgG | S1 | CMIA | S/CO | ||
| SARS-CoV-2 IgG N on Alinity | IgG | N | CMIA | S/CO | Fred Hutchinson Cancer Research Center |
|
| SARS-CoV-2 IgG S1 on Alinity |
IgG |
S1 |
CMIA |
AU/mL |
||
| Bio-Rad |
Platelia SARS-CoV-2 Total Ab (Evolis) | Total Ig | N | One-step antigen capture | S/CO | BloodWorks NorthWest |
| BioPlex 2200 SARS-CoV-2 IgG Panel |
IgG |
RBD, S1, S2, N |
Multiplexed microbeads two-step assay |
S/CO |
||
| Quotient |
MosaiQ COVID-19 Antibody Microarray |
IgM/IgG |
S1/S2 |
Array |
Qualitative only |
|
| Diazyme | DZ-Lite SARS CoV-2 | IgG | N & S1/S2 | IgG microbead CLIA | S/CO | |
| Beckman Coulter | Access SARS-CoV-2 IgG | IgG | S1 RBD | IgG 2-step paramagnetic particle CLIA | S/CO | University of California–Irvine |
| Wantai | SARS-CoV-2 Total Ig | Total Ig | S1 RBD | Total Ig sandwich ELISA | S/CO | Sanquin |
*Ab, antibody; Ag, antigen; AU, arbitrary units; CMIA, chemiluminescent microparticle immunoassay; CLIA, chemiluminescent immunoassay;.COVID-19, coronavirus disease; EIA, enzyme immunoassay; Ig, immunoglobulin; N, nucleocapsid; RBD, receptor binding domain; RU, relative units; S, spike protein; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S/CO, signal to cutoff ratio; †Current US regulatory status available at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2.